Claims for Patent: 10,500,287
✉ Email this page to a colleague
Summary for Patent: 10,500,287
| Title: | Amphipathic peptide |
| Abstract: | The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy. For example, the peptide may be used as a therapeutic agent delivery system, in which the therapeutic agent may include nucleic acids or other small molecules. |
| Inventor(s): | Helen McCarthy, Aleksey Zholobenko, Ashley Davison, Tracy Robson |
| Assignee: | Phion Therapeutics Ltd |
| Application Number: | US16/215,183 |
Details for Patent 10,500,287
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Auxilium Pharmaceuticals, Inc. | XIAFLEX | collagenase clostridium histolyticum | For Injection | 125338 | February 02, 2010 | ⤷ Start Trial | 2038-12-10 |
| Glaxosmithkline Biologicals | AREXVY | respiratory syncytial virus vaccine, adjuvanted | For Injection | 125775 | May 03, 2023 | ⤷ Start Trial | 2038-12-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,500,287
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014087023 | ⤷ Start Trial |
| United States of America | 9744244 | ⤷ Start Trial |
| United States of America | 2019091344 | ⤷ Start Trial |
| United States of America | 2018043031 | ⤷ Start Trial |
| United States of America | 2015314011 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
